Overview

NBE-002 in Patients With Advanced Solid Tumors

Status:
Active, not recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NBE-Therapeutics AG

Collaborator:

Cmed Clinical Services